Clinical outcomes of pembrolizumab therapy in advanced‐<scp>NSCLC</scp> patients with poor performance status (≥3) and high <scp>PD‐L1</scp> expression (<scp>TPS</scp> ≥50%): A case series
Thoracic cancer